Nanjing Hicin Pharmaceutical Co (SZSE:300584) Debt-to-Equity : 0.27 (As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Nanjing Hicin Pharmaceutical Co Debt-to-Equity?

Nanjing Hicin Pharmaceutical Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥270.6 Mil. Nanjing Hicin Pharmaceutical Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥0.0 Mil. Nanjing Hicin Pharmaceutical Co's Total Stockholders Equity for the quarter that ended in Mar. 2024 was ¥1,000.9 Mil. Nanjing Hicin Pharmaceutical Co's debt to equity for the quarter that ended in Mar. 2024 was 0.27.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Nanjing Hicin Pharmaceutical Co's Debt-to-Equity or its related term are showing as below:

SZSE:300584' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.03 Med: 0.19 Max: 0.27
Current: 0.27

During the past 12 years, the highest Debt-to-Equity Ratio of Nanjing Hicin Pharmaceutical Co was 0.27. The lowest was 0.03. And the median was 0.19.

SZSE:300584's Debt-to-Equity is ranked better than
52.96% of 846 companies
in the Drug Manufacturers industry
Industry Median: 0.3 vs SZSE:300584: 0.27

Nanjing Hicin Pharmaceutical Co Debt-to-Equity Historical Data

The historical data trend for Nanjing Hicin Pharmaceutical Co's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nanjing Hicin Pharmaceutical Co Debt-to-Equity Chart

Nanjing Hicin Pharmaceutical Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.19

0.25

0.19

0.27

Nanjing Hicin Pharmaceutical Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial															0.21	0.21	0.23	0.27	0.27

Competitive Comparison of Nanjing Hicin Pharmaceutical Co's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Nanjing Hicin Pharmaceutical Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nanjing Hicin Pharmaceutical Co's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Nanjing Hicin Pharmaceutical Co's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Nanjing Hicin Pharmaceutical Co's Debt-to-Equity falls into.

Nanjing Hicin Pharmaceutical Co Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Nanjing Hicin Pharmaceutical Co's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(270.998	+	0)	/	987.496
	=	0.27

Nanjing Hicin Pharmaceutical Co's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(270.555	+	0)	/	1000.861
	=	0.27

Nanjing Hicin Pharmaceutical Co (SZSE:300584) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Nanjing Hicin Pharmaceutical Co Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Nanjing Hicin Pharmaceutical Co's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Nanjing Hicin Pharmaceutical Co (SZSE:300584) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Nanjing Hicin Pharmaceutical Co Ltd (SZSE:300584) » Definitions » Debt-to-Equity

Traded in Other Exchanges

N/A

Address

Heng Road 1, Nanjing Economic and Technological Development Zone, Jiangsu Province, Nanjing, CHN, 210009

Website

http://www.hicin.cn

Nanjing Hicin Pharmaceutical Co Ltd is a China-based company engaged in producing pharmaceutical preparations. In addition, it is also involved in manufacturing synthetic chemicals, conducting new drug research and development as well as technical transferring. The company produces series of the medicines such as antivirals, antibiotics, endocrine drugs, gastrointestinal drugs, orthopedic drugs, drugs for the cardio-cerebral system and immuno-modulate agents. The active pharmaceutical ingredients, omeprazole sodium for injection, cefepime hydrochloride for Injection and lansoprazole tablets are exported by the firm into South-Asian countries, South-American countries and European countries.

Executives

Cao Yu Ping	Directors, executives
Yan Mei Qiang	Directors, executives
Jiang Xiang Ming	Executives
Gu Hai	Independent director

Nanjing Hicin Pharmaceutical Co (SZSE:300584) Headlines

No Headlines